Interest for RNA Therapy Deals Keeps Growing Among Big Pharmaceuticals

Recent months have been filled with announcements of major investments in RNA-based therapies by large pharmaceutical companies. Among these deals are acquisitions, partnerships, license agreements or new infrastructure, a continuing trend indicating the pharmaceutical industry’s growing interest in RNA technologies and therapies. This upswell may suggest that even more significant investments are on the horizon and that the future of RNA-based therapies is viewed with confidence by investors. Below is a non-exhaustive list of key announcements, made from April to June 2025.

April 18, 2025: Sanofi announces a new excellence unit to accelerate vaccine development, including mRNA vaccines

Article in French: https://www.sanofi.fr/fr/media/sanofi-today/notre-science/une-nouvelle-unite-dexcellence-a-marcy-letoile-pour-accelerer-le-developpement-de-vaccins

29 avril, 2025: Eli Lilly pens Creyon Bio AI oligonucleotide pact with $1B in biobucks on the table

https://www.fiercebiotech.com/biotech/eli-lilly-pens-creyon-bio-ai-oligonucleotide-pact-1b-biobucks-table

April 30, 2025 : Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

https://www.novartis.com/news/media-releases/novartis-acquire-regulus-therapeutics-and-farabursen-investigational-microrna-inhibitor-treat-adpkd-most-common-genetic-cause-renal-failure

NOTE : Novartis the acquisition of Regulus Therapeutics on june 25, 2025

Article en anglais : https://www.novartis.com/news/media-releases/novartis-completes-acquisition-regulus-therapeutics

May 14, 2025 : AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas

https://news.abbvie.com/2025-05-14-AbbVie-and-ADARx-Pharmaceuticals-Announce-Collaboration-and-License-Option-Agreement-to-Develop-Next-Generation-siRNA-Therapies-Across-Multiple-Therapeutic-Areas

May 15, 2025: Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics

https://www.prnewswire.com/news-releases/rznomics-enters-global-licensing-agreement-with-eli-lilly-for-rna-editing-therapeutics-302456852.html

May 27, 2025: Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

https://investors.biogen.com/news-releases/news-release-details/biogen-and-city-therapeutics-announce-strategic-research

June 16, 2025: Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-nears-13-billion-deal-gene-editing-biotech-verve-therapeutics-ft-2025-06-16/

June 30, 2025: AbbVie to buy Capstan for up to $2.1 billion in immunology push

https://www.reuters.com/legal/transactional/abbvie-buy-capstan-therapeutics-up-21-billion-2025-06-30